ROYALTY PHARMA INVESTMENTS 2019 ICAV

PrivateCIK: 1909645
Location

NEW YORK, NY

ROYALTY PHARMA INVESTMENTS 2019 ICAV enters EPIZYME, INC. with 22.67M shares — 100% direct ownership

Full direct ownership at entry is the strongest form of insider alignment with shareholders.

Direct
IssuerEPIZYME, INC.CIK 1571498
Director10% Owner
Since Jan 2022
22.67M
Baseline shares
100% direct
22.67M
Direct ownership
1 position
0.00
Derivative underlying
0 instruments
1
Security positions
All direct
Non-Derivative Holdings1

Common Stock

Direct
Shares owned22.67M
Total
22.67M direct22.67M
Derivative Holdings0
No derivative holdings reported
ROYALTY PHARMA INVESTMENTS 2019 ICAV — Initial Ownership Disclosure (Form 3) Filed Feb 9, 2022 | Finecho